Guggenheim has elevated Spyre Therapeutics to the firm’s top pick in the biotechnology sector after the company revealed 12-week topline results for SPY003 from the Phase II SKYLINE-UC monotherapy study. SPY003 is described as a longer-acting anti-IL-23 monoclonal antibody targeted for ulcerative colitis.
The Phase II study assessed three monotherapy arms. Enrollment included roughly 43 patients in the SPY001 arm, 48 in SPY002, and 44 in SPY003. The 12-week topline readout for SPY003 showed clinical outcomes that Guggenheim characterized as consistent with other IL-23p19 comparator drugs.
Specifically, SPY003 achieved 20% clinical remission and 30% endoscopic remission at the 12-week mark. The compound also produced a negative 10.0 change in the Robarts Histopathology Index, a measure reported in the topline disclosure. Guggenheim highlighted durability as a potential differentiator for SPY003, noting its positioning as a candidate for combination therapy approaches.
The trial population included a notable proportion of advanced therapy-experienced patients - approximately 41% - with a high share having previously received two or more advanced therapies, including patients with prior exposure to JAK inhibitors and IL-12/23 agents. Safety observations in Part A were described as consistent with the IL-23p19 class; there were no drug-related serious adverse events and no adverse events that led to study discontinuation.
Completion of Part A permits progression to Part B, a placebo-controlled stage that is currently enrolling patients. Part B will evaluate two dose levels of each monotherapy and will include three high-dose combination therapy arms. Topline induction data from Part B are expected in 2027, according to the company’s trial design timeline.
Looking beyond ulcerative colitis, Spyre has another clinical catalyst expected in the fourth quarter of 2026. The SPY072 SKYWAY-RD program, which investigates indications in psoriatic arthritis and axial spondyloarthritis, is slated to deliver data in late 2026. Guggenheim cited Spyre as one of the better-positioned companies working on longer-acting monoclonal antibodies for inflammatory bowel disease and related disorders.
In a separate update, Spyre reported topline results from a rheumatoid arthritis sub-study of SPY072. The company stated that the magnitude of effect observed in that sub-study did not meet its internal threshold to prioritize monotherapy development for SPY072 in rheumatoid arthritis.
Following that announcement, Wolfe Research downgraded the company to Peerperform from Outperform. Other firms, including Baird, Guggenheim, and Stifel, maintained or reiterated favorable ratings. The market reaction included visible trading in the company’s shares, with pre-market and intraday moves noted in trading data shown alongside the company profile.
For investors and market participants evaluating Spyre, the SPY003 Phase II topline readout and the pathway into a placebo-controlled Part B represent the near-term informational milestones. The upcoming SPY072 SKYWAY-RD readout in late 2026 and the Part B topline in 2027 are the next scheduled catalysts that market watchers will likely track closely.
While the Part A safety profile and the reported efficacy metrics for SPY003 align with IL-23p19-class expectations, the company’s development priorities for SPY072 will reflect the company’s internal assessments of monotherapy viability following the rheumatoid arthritis sub-study results.